Overview

On Open-Label Study in Participants With Systemic Lupus Erythematosus

Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this SLE study is to evaluate the long-term safety and efficacy of LY2127399 in eligible SLE participants who have completed the core studies (NCT01196091) (NCT01205438).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Antibodies, Monoclonal